摘要
目前临床治疗帕金森病主要以左旋多巴为代表的多巴胺替代疗法为主,存在着药物副作用较多,不能阻止病情进展等不利因素;手术治疗在近年有所发展,但也存在患者适应证有限,长期疗效较差等缺陷;因而干细胞成为帕金森病等各种神经退行性疾病治疗研究的焦点。胚胎干细胞可以在相关因素作用下定向诱导分化形成神经细胞,通过移植干细胞分化成为多巴胺能神经元而行使正常细胞功能、多巴胺能神经元保护及营养作用、促进内源性多巴胺能神经发生等途径应用于治疗帕金森病等神经系统退行性疾病,但是依然存在一定的副作用,还需要进行大量的实验研究和临床试验。胚胎干细胞为治疗帕金森病开辟了一个新的技术平台,在神经系统退行性疾病治疗领域临床应用前景广阔。
At present L-dopa as representative＇s dopamine substitution treatment primarily is mainly taken in clinic to treat Parkinson＇ s disease, which has many drug side effect, and could not prevent the progress of patient＇s condition. The surgery therapy has the development in the recent years, but also has the flaws like patient＇s indication is limited; the long-term curative effect is not ideal. Thus, stera cells became the research focal point to cure Parkinson＇s disease and other nerve degenerative disease. Embryonic stem cells induced directional differentiation and formed nerve cells under the correlation factor function, through the mechanisms such as differen tiating the dopaminergic neuron through the transplanted stem cells to exercise the function of normal cells, the function of protection and the nutrition of the dopaminergic neuron, promoting endogenous dopaminergic nerve genesis and so on to cure nervous system degenerative disease like Parkinson＇s disease. But it still has certain side effects, and needs to undertake massive experimental studies and clinical trials. Embryonic stem cells provide a new technical platform for treating Parkinson＇s disease, which shows a promising prospect in treatment of the nervous system degenerative disease.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2008年第43期8549-8552,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
